MX2020014163A - Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. - Google Patents

Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Info

Publication number
MX2020014163A
MX2020014163A MX2020014163A MX2020014163A MX2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A MX 2020014163 A MX2020014163 A MX 2020014163A
Authority
MX
Mexico
Prior art keywords
solid forms
ynoyl
pyrazin
imidazo
pyrrolidin
Prior art date
Application number
MX2020014163A
Other languages
English (en)
Inventor
Fritz Blatter
Jerry Evarts
Tjeerd Barf
Tim Ingallinera
Edwin Aret
Cecile Krejsa
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020014163(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MX2020014163A publication Critical patent/MX2020014163A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)

Abstract

En algunas modalidades, la invención se refiere a formas sólidas cristalinas, incluyendo polimorfos, hidratos y formas de sal, de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pi razin-1-il)-N-(piridin-2-il)benzamida. En algunas modalidades, la invención también se refiere a composiciones farmacéuticas que contienen las formas sólidas cristalinas, y a métodos para tratar afecciones o trastornos administrando a un sujeto una composición farmacéutica que incluye las formas, incluyendo composiciones farmacéuticas y métodos para superar los efectos de los agentes reductores de ácido. Fórmula (I). (ver Fórmula).
MX2020014163A 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. MX2020014163A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28
PCT/IB2016/053988 WO2017002095A1 (en) 2015-07-02 2016-07-01 Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Publications (1)

Publication Number Publication Date
MX2020014163A true MX2020014163A (es) 2022-09-29

Family

ID=56363881

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020014163A MX2020014163A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
MX2018000179A MX2018000179A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018000179A MX2018000179A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Country Status (29)

Country Link
US (6) US9796721B2 (es)
EP (4) EP3317281B1 (es)
JP (3) JP6829215B2 (es)
KR (1) KR20180048593A (es)
CN (2) CN108349978B (es)
AU (2) AU2016286548B2 (es)
CA (1) CA2991096A1 (es)
CL (1) CL2017003445A1 (es)
CY (3) CY1124519T1 (es)
DK (3) DK3613745T3 (es)
ES (3) ES2946489T3 (es)
FI (1) FI3954690T3 (es)
HK (1) HK1250511A1 (es)
HR (3) HRP20230417T1 (es)
HU (3) HUE049989T2 (es)
IL (3) IL293821A (es)
LT (3) LT3954690T (es)
MA (1) MA50817B1 (es)
MD (1) MD3317281T2 (es)
MX (2) MX2020014163A (es)
MY (1) MY193514A (es)
PL (3) PL3613745T3 (es)
PT (3) PT3954690T (es)
RS (3) RS60411B1 (es)
RU (1) RU2018103913A (es)
SG (1) SG10201913796UA (es)
SI (3) SI3317281T1 (es)
WO (1) WO2017002095A1 (es)
ZA (2) ZA201800329B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE056329T2 (hu) * 2014-08-11 2022-02-28 Acerta Pharma Bv BTK-inhibitor és BCL-2-inhibitor terápiás kombinációi
PT3954690T (pt) 2015-07-02 2023-06-06 Acerta Pharma Bv Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida
US10899767B2 (en) * 2016-10-05 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof
WO2018115965A1 (en) * 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN110312723B (zh) * 2017-02-20 2022-02-11 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途
EP3600314A1 (en) 2017-03-27 2020-02-05 Tesaro, Inc. Niraparib compositions
CA3058372A1 (en) * 2017-03-27 2018-10-04 Tesaro, Inc. Niraparib formulations
WO2018229613A1 (en) * 2017-06-13 2018-12-20 Dr. Reddy's Laboratories Limited Solid forms of acalabrutinib and process for preparation thereof
WO2019041026A1 (en) * 2017-08-29 2019-03-07 Apotex Inc. NEW CRYSTALLINE FORMS OF ACALABRUTINIB
WO2019067634A1 (en) 2017-09-26 2019-04-04 Tesaro, Inc. NIRAPARIB FORMULATIONS
WO2019105359A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Acalabrutinib的晶型及其制备方法和用途
KR20200106511A (ko) * 2018-01-05 2020-09-14 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 아칼라브루티닙의 신규 결정형 및 그 제조방법 및 용도
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
CN110650960B (zh) * 2018-04-26 2021-08-24 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
EP3587421A1 (en) 2018-06-29 2020-01-01 Sandoz AG Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
WO2020053795A2 (en) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Process for the preparation of acalabrutinib and its intermediates
EP3830091A1 (en) 2018-09-25 2021-06-09 Cipla Limited Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
EP3947386A1 (en) 2019-03-27 2022-02-09 Assia Chemical Industries Ltd Solid state forms of acalabrutinib
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021135346A1 (zh) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
WO2021239893A1 (en) 2020-05-29 2021-12-02 Bend Research, Inc. Amorphous solid dispersion of acalabrutinib
TW202200145A (zh) 2020-06-19 2022-01-01 荷蘭商艾森塔製藥公司 阿卡拉布替尼馬來酸鹽劑型
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
WO2022153330A1 (en) * 2021-01-13 2022-07-21 Natco Pharma Limited Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2023205279A1 (en) * 2022-04-19 2023-10-26 The Johns Hopkins University Improved raman spectroscopy with the addition of aromatic compounds

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
BR0014075A (pt) 1999-09-17 2002-07-16 Abbott Gmbh & Co Kg Inibidores de quinase como agentes terapêuticos
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
ATE525377T1 (de) 2003-10-15 2011-10-15 Osi Pharm Inc Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase
AP2139A (en) 2004-04-02 2010-08-21 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
KR101655455B1 (ko) 2005-09-09 2016-09-07 안젤리니 라보팜 엘엘씨 일일 1회 투여를 위한 트라조돈 조성물
EP2385053B1 (en) 2005-11-17 2013-10-02 OSI Pharmaceuticals, Inc. Intermediates for the preparation of fused bicyclic mTOR inhibitors
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US7651687B2 (en) 2006-03-13 2010-01-26 Osi Pharmaceuticals, Inc. Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors
PL2526771T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
AU2008232762B2 (en) 2007-03-28 2013-09-19 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
CN101896177A (zh) 2007-12-13 2010-11-24 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
WO2010126960A1 (en) 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
CA2787291C (en) 2010-02-08 2016-04-19 Msd Oss B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
ES2782873T3 (es) 2010-05-31 2020-09-16 Ono Pharmaceutical Co Derivado de purinona como inhibidor de Btk quinasa
EA201890869A3 (ru) 2010-06-03 2019-03-29 Фармасайкликс, Инк. Применение ингибиторов тирозинкиназы брутона (btk)
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
BR112013033534A2 (pt) 2011-06-28 2017-02-07 Pharmacyclics Inc métodos e composições para inibição de reabsorção de osso
AU2012283775A1 (en) 2011-07-13 2014-01-23 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
JP2014522860A (ja) 2011-07-19 2014-09-08 メルク・シャープ・アンド・ドーム・ベー・フェー Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
PE20141681A1 (es) 2011-07-19 2014-11-14 Merck Sharp And Dohme B V Inhibidores de btk
EP2771010A4 (en) 2011-10-19 2015-04-01 Pharmacyclics Inc USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US20140206681A1 (en) 2013-01-23 2014-07-24 Ronald M. Kim Btk inhibitors
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2014168975A1 (en) 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
EP2983669B1 (en) 2013-04-08 2018-10-24 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
CA2931431A1 (en) 2013-12-05 2015-06-11 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
KR101768402B1 (ko) 2013-12-13 2017-08-14 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
PT3954690T (pt) 2015-07-02 2023-06-06 Acerta Pharma Bv Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida

Also Published As

Publication number Publication date
US10167291B2 (en) 2019-01-01
EP4209493A1 (en) 2023-07-12
ZA201800329B (en) 2022-04-28
IL274066A (en) 2020-06-30
RS62455B1 (sr) 2021-11-30
JP6829215B2 (ja) 2021-02-10
MA50817B1 (fr) 2021-10-29
PT3317281T (pt) 2020-06-18
DK3954690T3 (da) 2023-06-06
ZA202000300B (en) 2022-03-30
PT3954690T (pt) 2023-06-06
ES2946489T3 (es) 2023-07-19
CY1124519T1 (el) 2022-03-24
PL3613745T3 (pl) 2022-01-31
RU2018103913A3 (es) 2019-12-31
IL293821A (en) 2022-08-01
SI3613745T1 (sl) 2021-12-31
CY1126103T1 (el) 2023-11-15
IL256633B (en) 2020-05-31
SG10201913796UA (en) 2020-03-30
DK3613745T3 (da) 2021-10-18
PT3613745T (pt) 2021-10-14
HRP20230417T1 (hr) 2023-07-07
JP7091494B2 (ja) 2022-06-27
RS64195B1 (sr) 2023-06-30
HK1250511A1 (zh) 2018-12-21
US11059829B2 (en) 2021-07-13
US10640509B2 (en) 2020-05-05
JP2018522877A (ja) 2018-08-16
ES2895802T3 (es) 2022-02-22
EP3954690A1 (en) 2022-02-16
HRP20200934T1 (hr) 2020-09-18
CN108349978B (zh) 2021-07-23
AU2016286548B2 (en) 2020-12-10
ES2797987T3 (es) 2020-12-04
KR20180048593A (ko) 2018-05-10
CA2991096A1 (en) 2017-01-05
AU2020277123B2 (en) 2022-09-29
US20180208596A1 (en) 2018-07-26
US20200255437A1 (en) 2020-08-13
DK3317281T3 (da) 2020-06-15
HUE056008T2 (hu) 2022-01-28
WO2017002095A1 (en) 2017-01-05
EP3613745B1 (en) 2021-09-01
MX2018000179A (es) 2018-06-27
US9796721B2 (en) 2017-10-24
LT3954690T (lt) 2023-05-25
SI3954690T1 (sl) 2023-07-31
HUE062258T2 (hu) 2023-10-28
EP3613745A1 (en) 2020-02-26
RU2018103913A (ru) 2019-08-02
US20220177476A1 (en) 2022-06-09
AU2020277123A1 (en) 2020-12-24
EP3954690B1 (en) 2023-04-05
EP3317281A1 (en) 2018-05-09
US20190337949A1 (en) 2019-11-07
HRP20211511T1 (hr) 2021-12-24
CL2017003445A1 (es) 2018-05-11
AU2022291635A1 (en) 2023-02-02
LT3613745T (lt) 2021-10-11
IL256633A (en) 2018-02-28
EP3317281B1 (en) 2020-04-22
US20220348582A1 (en) 2022-11-03
PL3317281T3 (pl) 2020-11-02
MA50817A (fr) 2021-04-21
CN113480542A (zh) 2021-10-08
CY1124815T1 (el) 2022-11-25
MY193514A (en) 2022-10-17
AU2016286548A1 (en) 2018-02-01
US20170029428A1 (en) 2017-02-02
MD3317281T2 (ro) 2020-07-31
CN108349978A (zh) 2018-07-31
IL274066B (en) 2022-07-01
PL3954690T3 (pl) 2023-08-14
RS60411B1 (sr) 2020-07-31
HUE049989T2 (hu) 2020-11-30
JP2021073235A (ja) 2021-05-13
JP2022120156A (ja) 2022-08-17
LT3317281T (lt) 2020-07-27
FI3954690T3 (fi) 2023-05-31
US11820777B2 (en) 2023-11-21
SI3317281T1 (sl) 2020-08-31

Similar Documents

Publication Publication Date Title
MX2020014163A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
NZ708593A (en) Novel pyrazole derivative
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12015501661B1 (en) Pyridone amides as modulators of sodium channels
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX2015009950A (es) Compuestos de imidazopiridina y sus usos.
MX2015009591A (es) Amidas como moduladores de canales de sodio.
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
GB201104267D0 (en) Pyrrolopyridineamino derivatives
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
PH12018501285A1 (en) Alkyl dihydroquinoline sulfonamide compounds
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
IN2014KN00849A (es)